Fermentalg exceeds its sales forecasts and succeeds in its industrial transfer

Fermentalg, a biotechnology company specializing in microalgae, announced strong sales growth in the second quarter of 2024. This acceleration allows the company to exceed its financial objectives, with an expected turnover in excess of €6 million for the first half, thus surpassing the target of €10 million for the full year.

Fermentalg also presented a series of innovations at Vitafoods Europe 2024, including the expansion of its DHA ORIGIN® range. These products target various market segments, including formulas for pregnant women and infant development, as well as dietary supplements for the entire family. Fermentalg underlines its commitment to innovation and the diversity of its commercial offer.

The mentioned success also includes the end of the transfer of production to HuvePharma, which positions Fermentalg as a major European player in the production of algal omega-3. This partnership promises secure localized production, meeting the demand for sustainability and reducing geopolitical risks.